UNIME University, R. Ten Fernando Tuy, n.168/902, Salvador, BA, 41830498, Brazil.
Unime Medical School, Lauro de Freitas, Brazil.
Lasers Med Sci. 2023 Apr 17;38(1):102. doi: 10.1007/s10103-023-03771-9.
This study was designed to compare the efficacy of selective laser trabeculoplasty (SLT) and micropulse laser trabeculoplasty (MLT) in patients with primary open angle glaucoma (POAG) requiring additional IOP control. In this retrospective, comparative study, we reviewed the charts of POAG patients requiring additional IOP lowering, who underwent either SLT or MLT and were followed for at least one year. We evaluated mean intraocular pressure (IOP), mean IOP reduction from baseline and mean number of glaucoma medications 1, 3, 6 and 12 months after treatment. Success rates (success defined as IOP ≤ 21 mmHg and ≥ 20% reduction from baseline IOP without additional medications, new laser session, or glaucoma surgery) at one year were also compared. A total of 98 POAG patients were included, 52 individuals in the SLT group and 46 in the MLT group. Laser treatment resulted in significant mean IOP reductions from baseline in both groups (SLT = -6.0 ± 3.3 mmHg (24.9%) and MLT = -5.8 ± 2.6 mmHg (23.4%)) (p < 0.001). However, there was no statistically significant difference between the mean IOP reductions in both groups (p = 0.74). At 12 months, the mean number of glaucoma medications was significantly smaller in the SLT group (1.17 + 0.4) when compared to the MLT group (2.21 + 0.2) (p = 0.001). Additionally, after 12 months, success was obtained in 32 (61.5%) SLT cases compared to 27 (58.7%) MLT-treated eyes (p = 1.0). MLT and SLT are both effective in controlling the IOP in POAG patients requiring additional IOP reduction. However, after 12 months, SLT demonstrated a greater efficacy in reducing medication burden when compared to MLT.Trial registration: CEP/CONEP/MS Brazil 40948620.9.0000.5600.
这项研究旨在比较选择性激光小梁成形术(SLT)和微脉冲激光小梁成形术(MLT)在需要进一步降低眼压的原发性开角型青光眼(POAG)患者中的疗效。在这项回顾性比较研究中,我们回顾了需要进一步降低眼压的 POAG 患者的图表,这些患者接受了 SLT 或 MLT 治疗,并至少随访了一年。我们评估了治疗后 1、3、6 和 12 个月的平均眼内压(IOP)、基线时的平均IOP 降低以及平均降眼压药物数量。还比较了一年时的成功率(成功定义为眼压≤21mmHg,且与基线眼压相比降低≥20%,无需额外药物、新激光治疗或青光眼手术)。共有 98 名 POAG 患者入组,其中 SLT 组 52 例,MLT 组 46 例。激光治疗使两组的平均眼压均显著降低(SLT=-6.0±3.3mmHg(24.9%)和 MLT=-5.8±2.6mmHg(23.4%))(p<0.001)。然而,两组的平均眼压降低无统计学差异(p=0.74)。在 12 个月时,SLT 组的平均降眼压药物数量明显少于 MLT 组(1.17±0.4 与 2.21±0.2)(p=0.001)。此外,12 个月后,32 例(61.5%)SLT 病例和 27 例(58.7%)MLT 治疗眼获得成功(p=1.0)。SLT 和 MLT 均可有效控制需要进一步降低眼压的 POAG 患者的眼压。然而,12 个月后,与 MLT 相比,SLT 在降低药物负担方面显示出更大的疗效。试验注册:CEP/CONEP/MS 巴西 40948620.9.0000.5600.